News | July 17, 2023
Evonik and Heraeus cooperate to expand the range of services for highly potent API
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
